Clinical trials: Recurrent Head and Neck Carcinoma
Recurrent, Nasopharyngeal Carcinoma
Treatment Result of KTP Laser Nasopharyngectomy in Recurrent NPC Patients
Investigate the treatment result of KTP laser nasopharyngectomy in recurrent NPC patients
- Trial name
- NCT00364962
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma
MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
This phase II trial studies the effect of pemetrexed and pembrolizumab in treating patients with salivary gland cancer that has come back (recurrent) and/or has spread to other places in the body (metastatic).
- Conditions
- Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8, Adenoid Cystic Carcinoma
- Trial name
- NCT04895735
- Testing
- Pembrolizumab, Pemetrexed Disodium, Biospecimen Collection
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Mayo Clinic
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
Randomized phase II trial to study the effectiveness of ixabepilone in treating patients who have metastatic or recurrent head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00033618
- Testing
- ixabepilone, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of the Head and Neck
A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck
The investigators will perform a randomized phase II study to investigate if the addition of cetuximab to MTX is beneficial for the patient.
- Trial name
- COMMENCE (NCT02054442)
- Testing
- Cetuximab, Methotrexate
- Where
- 8 sites in Netherlands
- Volunteers
- 52 people
- Sponsor
- Radboud University Medical Center
Esophageal Squamous Cell Carcinoma, Apatinib
Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer
It was difficult to obtain clinical benefits through traditional chemotherapy and radiotherapy for the patients who have recurrence or metastasis tumor even though they have received first-line chemotherapy or combined…
- Conditions
- Esophageal Squamous Cell Carcinoma, Apatinib, Recurrence, Metastasis
- Trial name
- NCT03913182
- Testing
- apatinib
- Where
- China
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Shanghai Chest Hospital
Colorectal Cancer, Esophageal Cancer
Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer
RATIONALE: Monoclonal antibodies such as ABX-EGF can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00004879
- Testing
- panitumumab
- Where
- 2 sites in United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Head and Neck Cancer, Mucositis
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
RATIONALE: Doxepin hydrochloride may be an effective treatment for oral mucositis pain in patients undergoing radiation therapy with or without chemotherapy.
- Conditions
- Head and Neck Cancer, Mucositis, Oral Complications of Radiation Therapy, Pain
- Trial name
- NCT01156142
- Testing
- doxepin hydrochloride
- Where
- 120 sites in United States
- Volunteers
- 155 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Head and Neck Cancer
Biomarkers in Patients With Head and Neck Cancer and in Healthy Volunteers
RATIONALE: Studying samples of blood, tissue, and saliva in the laboratory from patients with cancer and from healthy volunteers may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00899769
- Testing
- protein expression analysis, proteomic profiling, immunoenzyme technique
- Where
- 3 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Recurrent Adenoid Cystic Carcinoma of the Salivary Glands, Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
This is a non-randomized, phase II, open label study of dovitinib in patients with progressive, recurrent and/or metastatic adenoid cystic carcinoma (ACC).
- Conditions
- Recurrent Adenoid Cystic Carcinoma of the Salivary Glands, Metastatic Adenoid Cystic Carcinoma of the Salivary Glands, Salivary Gland Cancers, ACC
- Trial name
- DOVE (NCT01678105)
- Testing
- Dovitinib
- Where
- 4 sites in Canada
- Volunteers
- 21 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Thyroid Cancer, Recurrence
Diagnostic Utility of [18F]-FDG-PET/CT and [124I]-PET/CT for Detection of Recurrence in Differentiated Thyroid Carcinoma
Several studies have indicated that [124I]-PET/CT or [18F]-FDG-PET/CT may be useful to locate recurrent differentiated thyroid carcinoma lesions in patients with elevated thyroglobulin levels but who do not show pathological…
- Trial name
- NCT01374659
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Korean Association of Endocrine Surgeons
Esophageal Cancer, Gastric Cancer
Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004127
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 35 people
- Sponsor
- University of Chicago
Nasopharyngeal Carcinoma
Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
The study is to evaluate the clinical efficacy of apatinib mesylate tablets combined with PD-1 in the treatment of recurrent and metastatic nasopharyngeal carcinoma after IMRT with concurrent chemotherapy,including The Overall…
- Trial name
- NCT04350190
- Testing
- Apatinib mesylate tablet, PD-1
- Where
- 5 sites in China
- Volunteers
- 25 people
- Sponsor
- Wei Jiang
Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer
Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery
This phase I trial is studying the side effects and best dose of iodine I 131 when given together with pazopanib hydrochloride in treating patients with recurrent and/or metastatic thyroid cancer previously treated with iodine I…
- Conditions
- Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer
- Trial name
- NCT01413113
- Testing
- pazopanib hydrochloride, iodine I 131
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Esophageal Cancer
A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent/Metastatic Esophageal Squamous Cell Carcinomar (ESCC) Failed or…
- Trial name
- NCT06769113
- Testing
- HLX43
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Shanghai Henlius Biotech
Squamous Cell Carcinoma of Head and Neck
SHR-1701 in Patients With Recurrent/Metastatic Scchn
This is an open label, single-arm, multi-center, phase II study of SHR-1701 in patients with recurrent/metastatic SCCHN
- Trial name
- NCT04650633
- Testing
- SHR-1701
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Head and Neck Cancer, Oral Complications
Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy at different times of the day may affect the chance of developing side effects such as mucositis.
- Trial name
- NCT00004234
- Testing
- management of therapy complications, radiation therapy
- Where
- 14 sites in Canada
- Sponsor
- NCIC Clinical Trials Group
Head and Neck Cancer
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
The BURAN study is a randomized, open-label phase III study to assess the treatment effect of once-daily buparlisib in combination with weekly paclitaxel compared to weekly paclitaxel alone in patients with refractory, recurrent…
- Trial name
- BURAN (NCT04338399)
- Testing
- Buparlisib & Paclitaxel
- Where
- 162 sites in United States, Argentina and 15 more
- Volunteers
- 487 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Metastatic Head and Neck Squamous Cell Carcinoma, Advanced Malignancies
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this study is to determine the safety, tolerability, efficacy, PK and pharmacodynamics of INCAGN01876 when given in combination with retifanlimab.
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Advanced Malignancies, Recurrent Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05359692
- Testing
- INCAGN01876, retifanlimab
- Where
- 17 sites in United States
- Sponsor
- Incyte Biosciences International Sàrl
Anaplastic Thyroid Cancer, Recurrent Thyroid Cancer
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
This phase II trial is studying how well sorafenib works in treating patients with advanced anaplastic thyroid cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by…
- Trial name
- NCT00126568
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.